Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer

Cancer Science

Volumn 107, Issue 7, 2016, Pages 936-943

  Yamada, Takeshi ^a   Iwai, Takuma ^a   Takahashi, Goro ^a   Kan, Hayato ^a   Koizumi, Michihiro ^a   Matsuda, Akihisa ^a   Shinji, Seiichi ^a   Yamagishi, Aya ^a   Yokoyama, Yasuyuki ^a   Tatsuguchi, Atsushi ^a   Kawagoe, Tatsuro ^a   Kitano, Shiro ^b   Nakayama, Masato ^b   Matsumoto, Satoshi ^a   Uchida, Eiji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOPPAN PRINTING CO LTD   (Japan)

Author keywords

Anti EGFR antibody; circulating cell free DNA; circulating tumor DNA; EGFR blockade; KRAS

Indexed keywords

CETUXIMAB; CIRCULATING CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL SURGERY; CONTINUOUS INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATION; PLASMA; POINT MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TUMOR RECURRENCE; VERY ELDERLY;

EID: 84978864137     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12959     Document Type: Article

References (32)

1. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
2. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992–5.
3. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023–34.
4. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279–86.
5. Bouchahda M, Karaboue A, Saffroy R et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010; 66: 605–9.
6. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790–9.
7. Mao C, Wu XY, Yang ZY et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015; 5: 8065.
8. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532–6.
9. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 2008; 14: 4141–5.
10. Mostert B, Jiang Y, Sieuwerts AM et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133: 130–41.
11. Fabbri F, Carloni S, Zoli W et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013; 335: 225–31.
12. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108–12.
13. Diehl F, Li M, Dressman D et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102: 16368–73.
14. Bando H, Yoshino T, Tsuchihara K et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011; 105: 403–6.
15. Lyamichev V, Mast AL, Hall JG et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 1999; 17: 292–6.
16. Kitano S, Myers J, Nakamura J et al. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS ONE 2013; 8: e62989.
17. Trevisiol C, Di Fabio F, Nascimbeni R et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers 2006; 21: 223–8.
18. Ryan BM, Lefort F, McManus R et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52: 101–8.
19. Yen LC, Yeh YS, Chen CW et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009; 15: 4508–13.
20. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18: 1177–85.
21. Thierry AR, Mouliere F, El Messaoudi S et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014; 20: 430–5.
22. Taly V, Pekin D, Benhaim L et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013; 59: 1722–31.
23. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51: 2116–20.
24. Lecomte T, Berger A, Zinzindohoue F et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100: 542–8.
25. Umetani N, Kim J, Hiramatsu S et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52: 1062–9.
26. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002; 101: 545–8.
27. Locker GY. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313–27.
28. Glover C, Douse P, Kane P et al. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis Colon Rectum 2002; 45: 476–84.
29. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–9.
30. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta 2007; 1775: 181–232.
31. Diaz LA Jr, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537–40.
32. Morelli MP, Overman MJ, Dasari A et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015; 26: 731–6.